

Reza Khosravan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4397960/publications.pdf>

Version: 2024-02-01

15
papers

612
citations

932766

10
h-index

996533

15
g-index

15
all docs

15
docs citations

15
times ranked

644
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment. <i>American Journal of Therapeutics</i> , 2005, 12, 22-34. | 0.5 | 140 |
| 2 | Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects. <i>Clinical Pharmacokinetics</i> , 2006, 45, 821-841. | 1.6 | 85 |
| 3 | The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 88-102. | 1.0 | 68 |
| 4 | Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 355-363. | 1.1 | 67 |
| 5 | Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 472-481. | 1.0 | 66 |
| 6 | Metabolism and Excretion of [¹⁴ C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 189-201. | 1.0 | 51 |
| 7 | Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018, 107, 237-245. | 1.2 | 37 |
| 8 | Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1251-1269. | 1.6 | 29 |
| 9 | Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 57-64. | 1.1 | 19 |
| 10 | Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 41-50. | 1.1 | 18 |
| 11 | Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. <i>AAPS Journal</i> , 2020, 22, 31. | 2.2 | 11 |
| 12 | A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status.. <i>Journal of Clinical Oncology</i> , 2012, 30, 363-363. | 0.8 | 9 |
| 13 | Population pharmacokinetics and pharmacodynamics of sunitinib in pediatric patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 181-192. | 1.1 | 7 |
| 14 | Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 621-634. | 1.1 | 3 |
| 15 | Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 343-352. | 0.6 | 2 |